RCUS
Arcus Biosciences, Inc.
NYSE · Healthcare · Biotechnology · US
$18.19
−2.26%Oct 26, 2026, 20:35 UTC
Arcus Biosciences, Inc. granted three new employees options to purchase a total of 10,650 shares of its common stock at an exercise price of $18.54 per share.
Source:Oct 21, 2026, 20:22 UTC
Arcus Biosciences, Inc. commenced an underwritten public offering of its common stock, with all shares offered by the company.
Oct 9, 2026, 20:35 UTC
Arcus Biosciences, Inc. granted two new employees options to purchase a total of 9,150 shares of its common stock at an exercise price of $23.83 per share.
Source:Sep 24, 2026, 20:35 UTC
Arcus Biosciences granted stock options to purchase 21,200 shares at $26.39 per share to four new employees.
Source:Sep 22, 2026, 12:30 UTC
Arcus Biosciences announced it will host an investor event on October 20, 2026 in New York City to present new data from the ARC-20 platform study evaluating casdatifan as a treatment for kidney cancer across multiple lines of therapy.
Source:Aug 25, 2026, 07:52 UTC
BlackRock Inc. acquired a new stake in Arcus Biosciences, Inc. during the second quarter, purchasing 16,416,249 shares valued at approximately $506.11 million, representing 13.05% ownership.
Source:Aug 11, 2026, 20:35 UTC
Arcus Biosciences' Compensation Committee granted a new employee options to purchase 2,850 shares of common stock at an exercise price of $28.72 per share.
Source:Aug 5, 2026, 00:00 UTC
Arcus Biosciences reported Q2 2026 total revenue of $41 million, a net loss of $91 million, and diluted EPS of -$0.72, with cash and marketable securities of $775 million as of June 30, 2026.
Jul 22, 2026, 20:30 UTC
Arcus Biosciences and Summit Therapeutics entered into a clinical trial collaboration to evaluate casdatifan combined with ivonescimab in kidney cancer.
Source:Jun 4, 2026, 16:55 UTC
Arcus Biosciences and Bristol Myers Squibb have formed a partnership to advance clinical studies of casdatifan combinations for kidney cancer.
Source: